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Abstract
The provenance of a piece of data refers to knowledge about its origin,
in terms of entities and actors involved in its creation, e.g. data sources
used, operations carried out on them, and users enacting those operations.
Provenance is used to better understand the data and the context of its pro-
duction, and to assess its reliability, by asserting whether correct procedures
were followed. Providing evidence for validating research is of particular
importance in the biomedical domain, where the strength of the results de-
pends on the data sources and processes used. In recent times, previously
manual processes have become fully or semi- automated, e.g. clinical trial re-
cruitment, epidemiological studies, diagnosis making. The latter is typically
achieved through interactions of heterogeneous software systems in multiple
settings (hospitals, clinics, academic and industrial research organisations).
Provenance traces of these software need to be integrated in a consistent and
meaningful manner, but since these software systems rarely share a common
platform, the provenance interoperability between them has to be achieved on
the level of conceptual models. It is a non-trivial matter to determine where
to start in making a biomedical software system provenance-aware. In this
paper, we specify recommendations to developers on how to approach prove-
nance modelling, capture, security, storage and querying, based on our expe-
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riences with two large-scale biomedical research projects: Translational Re-
search and Patient Safety in Europe (TRANSFoRm) and Electronic Health
Records for Clinical Research (EHR4CR). While illustrated with concrete
issues encountered, the recommendations are sufficiently high level so as to
be reusable across the biomedical domain.
Keywords: provenance, biomedical informatics
1. Introduction
Provenance aims to capture the origin of some data through details of
actions and actors involved in its creation. In scientific applications, prove-
nance helps us to understand research results [1]. For instance, a published
clinical study may contain a table showing the statistical significance of some
treatment on the case group, as opposed to the control sample. Provenance
of that table would consist of the statistical algorithms used, their parame-
terisation, data cleaning that was applied, case and control definitions, and
information about the data provider or the data gathering process used. In
some circumstances, a part of the process may change over time (e.g. tweak-
ing the case definition) causing the result to change, and the provenance
trace can provide clear information about how the result was obtained and
how it may be repeated or improved.
Provenance is directly contributing to several important goals that re-
search methodologies are trying to attain. In itself, provenance traces make
the research process auditable, by providing a standardised account of actions
that unfolded during the process execution. Combined with a formal model,
such as a business workflow specification, provenance ensures the results are
verifiable. Finally, when the program executables are provided together with
the data used, they jointly ensure reproducibility of the research.
Biomedical research is characterised by the heterogeneity of the research
teams participating in projects, procedures they follow, and the data they
produce. A drug development pipeline would span a range of disciplines
from target identification via detection of candidate genes for drugs, to clin-
ical studies exploring the efficacy and drug safety. The need to capture
details of data produced at each step and the processes involved is persistent
throughout this process and benefits from common technical frameworks that
span different scientific domains and multiple teams. For example, collabo-
rative workflows [2] have proven to be highly useful in integrating microarray
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analysis with low-level gene annotation.
Auditability and verifiability of research data are also essential compo-
nents of data management in clinical research, due to the sensitivity and
importance of its impact on saving lives. This is reflected in popular stan-
dards such as GxP (including Good Clinical Data Management Practice and
Good Clinical Practice) [3], CONSORT for trial reporting [4], and STROBE
[5] for reporting observational studies. Of particular interest is ADAM [6]
produced by the Clinical Data Interchange Standards Consortium (CDISC),
which documents each derived variable (treatment, outcome, or covariate)
used in clinical trial analysis data sets, to enable review and re-creation of
published research. All of these standards take a retrospective view of data
provenance, as something that needs to be collected and described post-hoc.
As will be shown, successful provenance implementations adopt a prospective
view, automatically collecting this information in a single repository during
the life of a research project.
Reproducibility is also the focus of The Open Data initiative [7] which
aims to make publicly generated data free and available to everyone, in use-
ful formats, subject to proper attribution. Another part of that vision, di-
rectly relevant to health data management, is that any published research
study should be accompanied by the full data that it was derived from, thus
enabling the reader to verify the results for themselves. This approach is
increasingly taken up by scientific journals [8].
In this paper, we review the implications of provenance for biomedical re-
search by analysing the provenance requirements of two real-world use cases
from the clinical research domain, and propose recommendations on appro-
priate solutions for developing provenance capacity. In particular, we chose
the use cases that rely on the service oriented architecture paradigm to high-
light the importance of provenance in a complex computing system and reveal
the benefits that the provenance capacity may bring.
2. Background
The concept of provenance is well established in many disciplines [9, 10].
For example, in the study of fine art it refers to the trusted, documented
history of some work of art. Electronic tracking of provenance was origi-
nally studied in individual domains including geography or library studies,
or with regards to particular technologies, such as databases or workflow
systems. It was recognised that the same issues occurred in these different
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applications, and so similar solutions may apply. Simultaneously, there was
a push from many organisations and projects for a standard approach to
representing provenance, as this would then allow systems to be developed
with some guarantee that the provenance data held would be interpretable in
the future. Furthermore, it was understood that an important effect of hav-
ing common provenance representations would be that the history of data
could be traced across multiple heterogeneous systems, as the provenance
each system recorded would be interoperable and interconnectable with that
recorded by the others.
2.1. Provenance representation models
In the early days of the provenance efforts, several generic provenance
models were proposed [11, 12, 13]. Several metadata vocabularies also al-
lowed some limited provenance information to be expressed, particularly
Dublin Core [14] or Minimum Information About a Microarray Experiment
(MIAME) [15] for gene expression data.
Through merging the pioneering efforts of several research groups, a
community-driven provenance specification, the Open Provenance Model
(OPM) [16] became a de-facto standard representation for provenance in
many areas. OPM is a causal graph model, with edges denoting relationships
(X was caused by Y) and nodes representing the individual occurrences of
entities. The OPM type graph is shown on the left side of Figure 1. OPM
graphs describe the full lineage of a piece of data in terms of multiple events
(process instances) that led to it being produced. The nodes in the graph
can be of three types: artifacts, processes, and agents.
• Artifacts are pieces of data of fixed value and context, e.g. one version
of a data set, or a document, and are denoted by ovals in the provenance
graph.
• Processes are actions that are performed using artifacts to generate
other artifacts, e.g. a selection process uses the full set of eligible
patients and generates a subset of these with which to conduct the
trial. They are represented by rectangles in a provenance graph.
• Agents are the entities controlling process execution, either as human
actors or as non-mutable pieces of software. They are shown as oc-
tagons in the provenance graph.
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wasTriggeredBy
actedOnBehalfOf
wasInformedBy
Figure 1: OPM and PROV type graphs showing available kinds of nodes and edges in
each language
The various properties of artifacts, processes and agents are represented by
arbitrary key-value annotations to the nodes. These annotations can include
any contextual information, such as regarding the type, ownership, data
format, etc. of the data or activities represented by the nodes. Edges can
also have annotations to provide further information on how one occurrence
caused another.
Building on that and other work, the W3C standards body initiated a
working group to develop official W3C standards for provenance. The PROV
family of models [17], the type graph for which is shown on the right side
of Figure 1 is based on OPM, revising and extending it with better support
for attribution and evolution of entities over time. PROV activities denote
something that occurs over a period of time, and they both use and generate
PROV entities. PROV entities are things, whether data, physical or con-
ceptual. Unlike OPM artifacts, entities can be mutable and have a lifetime
between being generated and being invalidated (by activities). One entity
can be a specialisation of another entity in a particular context, e.g. a pa-
tient’s medical record with particular contents following a consultation is a
specialisation of that medical record as it has existed over time. PROV agents
denote that which has responsibility for something, commonly a person, or-
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ganisation or software agent. They may be responsible for an activity having
taken place, or for an entity existing. The latter can be used to attribute
authorship of some data to a person, for example. PROV also provides ba-
sic modelling infrastructure for describing data structures in the provenance,
through the use of collections and dictionaries. The nodes and edges of a
PROV graph can have attributes, which are the data defining their value
and context, e.g. the number of patients identified for a clinical trial or the
title of a report.
This type of provenance is sometimes referred to as retrospective prove-
nance, in that it captures historical data produced by execution of some
process model. Nomenclature used in [18] and [19] distinguishes prospective
provenance which is the representation of the process model that creates ret-
rospective provenance data, and the process provenance which looks into the
provenance of that process model itself. This categorisation is particularly
well-suited to systems where there is a single computational artifact pro-
ducing all the provenance data, such as a scientific workflow in a workflow
management system. Then the prospective provenance is captured by the
workflow being used, and the process provenance is the provenance of that
workflow as it evolves over time.
When provenance is represented by a graph model, such as OPM and
PROV, the queries are usually performed using a graph query language with
semantic extensions to integrate with the domain of interest. Graph query
languages have been extensively investigated for applications such as semi-
structured data, semantic graphs, transportation networks, social networks
and others. A good overview can be found in [20]. The typical queries in such
languages focus on subgraph matching, finding nodes connected by paths,
comparing and returning paths, aggregation, node creation, and approxi-
mate matching and ranking. Early languages include G[21] and GraphLog
[22], an extension of DataLog. Object-oriented graph models were introduced
in languages such as GraphDB [23], GOOD[24], Lorel[25], and Strudel[26].
UnQL [27] uses structural recursion and a functional model to work on semi-
structured data. YAGO/NAGA[28] was developed for semantic search en-
gines, and contains weighting elements that are used to represent the con-
fidence of information in the query result. These languages influenced the
semantics of the SPARQL language for querying RDF graphs [29], e.g. v1.1
of the standard included the capability to query paths using regular expres-
sions. With RDF commonly used for persisting provenance data, SPARQL
is frequently used as the language for querying provenance.
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2.2. Provenance of biomedical software
In biomedical research, the data (genotype and phenotype information
from multiple sources), the workflow (procedures carried out to perform the
data analysis) and the log records (recording of relevant events in those pro-
cedures) may be distributed among several heterogeneous and autonomous
information systems [30]. These information systems may be under the au-
thority of different healthcare actors such as general practitioners, hospitals,
hospital departments, etc, which form disconnected islands of information.
Provenance frameworks then take the additional role of verifying the adher-
ence of actors in the process to security policies in place.
The provenance of many pieces of information, such as a count of patients
eligible for a clinical trial, is derived from data in multiple sites. Knowing
the provenance of the results means having records of what occurred at each
of those sites, and integrating these. In order for this to happen, each site’s
software must generate records that can be integrated, i.e. that are interop-
erable, ideally by using the same base model.
When the tools share the same execution environment (workflow manage-
ment system, scripting engine etc.) this model can be based on the shared
framework [31, 32], but this is not an option in the presence of heterogeneous
software. Similarly affected is the prospective provenance aspect, which can-
not rely on describing a scientific workflow or another concrete process that
is generating provenance, but has to look into more abstract structures that
are shared between multiple software systems. Thus, interoperability is the
primary driver for such model-based approach to provenance.
Just because the full details of all processes in the system, and the data
they accessed, could be documented and made accessible to queriers, this
does not mean that any particular piece of provenance data should be com-
municated outside of a given site or that any particular individual should
have access to all provenance. The secure provenance problem [33] is the
task of providing assurances of integrity, confidentiality, and availability to
the tasks and provenance records. Preserving the confidentiality of prove-
nance data and verifiable application of security policies associated with it,
is of particular concern to biomedical research.
The biomedical domain includes a plethora of data models and ontolo-
gies, allowing distributed applications to share common terminology. Vast
majority of terminologies, formats, and standards in use are publicly avail-
able and managed, practice stemming from the need for public and govern-
mental scrutiny of medical guidelines. Thus, commercial organisations focus
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their business model around the data rather than proprietary formats that
would lock users into their software tools. For example, Clinical Data Inter-
change Standards Consortium, comprised of industrial, clinical, and research
organisations, is tasked by the US government to promote standards and
interoperability in the biomedical domain. Thus, as well as integrating the
recording and storage of provenance information into the existing software
of a distributed application, the model used for provenance needs to express
concepts specific to the biomedical domain, and so be integrated with those
vocabularies and models.
Ultimately, the value of recorded provenance data in biomedical domain
is that it provides answers to questions about the research conducted. How-
ever, once the users start working with provenance data, they may think of
new provenance questions they could answer. Therefore, the way in which
provenance is modelled and recorded needs to be future-proof, as far as is fea-
sible, in being able to answer provenance questions not considered at design
time.
In summary, the way in which provenance is modelled and recorded in a
biomedical research application needs to allow interoperability of provenance
between subsystems, provide confidentiality over portions of the provenance
data, be able to be integrated with domain models, and be future proof with
respect to new provenance questions that may arise.
3. Use cases
In this section we give a brief overview of the two research projects,
experiences of which motivate our general recommendations that follow. The
two projects, TRANSFoRm (Translational Research and Patient Safety in
Europe) [34] and EHR4CR (Electronic Health Records For Clinical Research)
[35] are investigating the integration of data required for clinical trials and
data routinely collected in medical practice.
Clinical trials are an important part of medical research and new drug
development. In a biomedical project, upon the satisfaction of the pre-clinical
trials, a set of tests have to be conducted with patients with specific health
conditions to generate safety and efficacy data. The number of patients
recruited for trials has to be sufficient so that the experiment results will be
statistically significant for examining the effectiveness of a new treatment.
However, recruiting patients with the predetermined characteristics for a
clinical trial is a time-consuming and costly process. Traditionally, clinical
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researchers have to communicate with a number of healthcare centres in order
to find eligible patients and suitable sites for conducting clinical trials. They
then have to go on to negotiate with individual centres in order to execute
the clinical trial with the eligible patients at each centre.
TRANSFoRm focuses on general practice and makes use of large collec-
tions of data collected therein, while EHR4CR is more concerned with the
hospital setting and integration of data from a larger number of specialist
data sources.
3.1. TRANSFoRm (Translational Research and Patient Safety in Europe)
The TRANSFoRm project is developing a common digital infrastructure
to support the vision of the learning health care system [36] through inte-
grating the data and workflows of clinical and research domains in primary
care. The project outputs include methods, models, services, validated archi-
tectures and clinical demonstrations of software to support this integration.
The software has been designed as a modular collection of tools that are de-
ployed in three software configurations: Epidemiological Study, Randomized
Clinical Trial, and Decision Support. These configurations directly support
the three use cases in the project: retrospective diabetes cohort study, gas-
troesophageal reflux disease clinical trial, and a diagnostic support system
for chest pain, abdominal pain, and dyspnoea.
At the heart of the Epidemiological Study software configuration is a se-
mantically aware Query Formulation Workbench, designed to enable easy
authoring of distributed searches to EHR and other clinical data sources,
using a controlled vocabulary service and appropriate standards-based tech-
nological solutions. An inherent problem in the design of clinical trials is
preserving the audit trail of the process through which these study eligibility
criteria are constructed.
The key provenance requirement in TRANSFoRm is to maintain a uni-
form audit trail across the different software tools and configurations, and
have it comply to Good Clinical Practice guidelines (GCP). This reflects
the project’s ambition to provide infrastructure for a wide variety of soft-
ware, with shared key components: security, privacy, vocabulary services,
and provenance. The designs of all software tools in TRANSFoRm are based
on the Clinical Research Information Model (CRIM) [37] that specifies all
process flows and data models that are required in TRANSFoRm use cases,
and is GCP-compliant. Thus, CRIM also defines the level of detail required
in the provenance traces.
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3.1.1. TRANSFoRm provenance model
CRIM is provided as an Unified Medical Language System (UMLS) model,
and as such unsuitable to be directly used for provenance representation.
Firstly, its syntax is not expressed in terms of OPM or PROV and therefore
not all their concepts fit the restrictions and logics behind provenance. Sec-
ondly, UMLS does not support semantic reasoning required for causality and
temporal queries, which are both highly relevant to provenance. Therefore,
instead of using it directly, CRIM was used as a basis for constructing the
Randomized Clinical Trials Ontology (RCTO), which placed all concepts and
actors from CRIM into an ontological structure, with explicit representation
of processes which were implicit in CRIM. As the next step, Randomized
Clinical Trials Provenance Ontology (RCTPO) was defined as extension of
RCTO with OPM provenance concepts, such as versioning relationships be-
tween artifacts and create/edit actions, annotations of documents with their
physical location, and links between agents, security information, and actions
performed.
As an example, the concept of an electronic case report form is defined
in CRIM as eCaseReportForm. In RCTO, it becomes an ontological con-
cept, linked to a ClinicalStudy concept, which is, in turn, linked to a Tri-
alProtocolDocument and an AdverseEffectProcedureDocument. In RCTPO,
eCaseReportForm is an instance of an OPM artifact, and represents the form
at a certain time point, with laterGenerationThan relationships to previous
and future versions, used relations to edit tasks using it, wasGeneratedBy
relations to the create/edit process that produced it, and all the structural
links to domain concepts inherited from RCTO. Since CRIM, and conse-
quently RCTO and RCTPO, implement Good Clinical Practice guidelines,
this enables provenance records to be used in providing parts of the audit
trail required by GCP. Full detail on how individual parts of CRIM were
mapped to provenance concepts can be found in [38].
RCTPO contains some non-domain content as well in order to support
the TRANSFoRm infrastructure middleware, message-passing and security.
All the tools or applications used in TRANSFoRm are registered in the prove-
nance store database, with the versioning and the link to the source/installation
repository also maintained. Each time a user logs into an application his
corresponding agent is retrieved or generated, a userSessionArtifact and a
createdSessionProcess are generated and connected to authentication and au-
thorisation processes. Following that, all consequent actions by the user in
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the application are all associated to the originalcreatedSessionProcess. This
results in large interconnected graphs containing full audit trail of the pro-
cesses, expressed in concepts that can be traced back to the CRIM conceptual
model.
3.1.2. Provenance templates
As discussed above, the lack of a common execution environment compli-
cates the capture of prospective provenance. Technologies such as D-PROV
[39] support such provenance by relying on workflows as means of producing
provenance data. TRANSFoRM did not have that option available, so the
solution was to introduce provenance template as a higher-level abstraction
of the provenance graph data. This construct specifies basic conceptual units
that a software tool may record in the provenance repository, e.g. an edit
operation on an eligibility criterion of a study, which is derived from the
model and that is translated into a concrete provenance trace by a mapping
model inside the provenance framework.
Provenance templates in TRANSFoRm use a graph syntax similar to
OPM graphs. The difference is that their artifact, process, and agent nodes
refer not to concrete instances in the past but to RCTPO domain concepts
that shall be used for instantiation. Further graphical constructs are intro-
duced to model subgraph pattern repetitions, node information description
and physical or logical distribution of graph segments. An example of a
provenance template is shown in Figure 2 describing a sequence of potential
edits happening on eligibility criteria that are associated with a protocol of a
clinical study. The multiple edits of the study, protocol and eligibility crite-
ria are sequential repetitions, while different user sessions can be created in
parallel by multiple users and software tool instances. A provenance graph
segment created using the template is shown in Figure 3 depicting a scenario
in which a researcher, TA, created a study with the protocol and eligibility
criteria specifying that study participants should be over 60 years and female,
while the other researcher, JR, modified it with another protocol specifying
that participants should have Body Mass Index (BMI) over 40.
Associated with each entity is a set of annotations, so for example, the
annotations for the eligibility criteria version 57 17 are:
Details for ClinicalStudyEligibilityCriteria 57_17:
WasDerivedFrom: OPMArtifact_50
WasGeneratedBy: OPMProcess_55
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AnnotationTime: 2013-10-03 07:01:56
Type: ClinicalStudyEligibilityCriteria; Artifact
Id: ItInst_1150449877_1380780116960_objectA2_
rcto:ClinicalStudyEligibilityCriteria
Value: Inclusion Criteria: Age > 60; Inclusion Criteria: Gender = F
The provenance data captured in this way are stored in a semantically
annotated database for later auditing and analysis. All provenance enti-
ties contain at least one annotation: their domain semantic type defined in
RCTPO and derived from the Clinical Research Information Model (CRIM).
The time of annotation, the TRANSFoRm module which generated the data,
and the physical allocation of the data itself are also always available. The
database is implemented in a standard relational DBMS, but supporting
both SQL queries, and SPARQL queries that can make use of semantic
annotations. The latter is achieved through the Data-to-Relational-Query
(D2RQ) tool [40], which provides mappings between relational schemata and
OWL/RDFS ontologies.
3.1.3. Securing provenance in TRANSFoRm
Within the TRANSFoRm architecture, the security solution layer is in
charge of ensuring the identities of TRANSFoRm users, and managing their
allowed actions. The security layer performs this by issuing SAML [41] asser-
tions to authenticated clients to establish that they are allowed to perform
a certain action. The provenance record of those actions is maintained sepa-
rately from the security layer and it contains the SAML assertion itself, which
holds no identifiable information, but allows invoking the security layer’s API
to extract additional information, e.g. why was the assertion issued or how
was the requesting user authenticated. The API calls are managed by the se-
curity layer, which can decide whether further information is available about
the SAML assertion for the user posing the question.
3.1.4. Queries and result visualisation
For auditing and querying of stored provenance data, TRANSFoRm pro-
vides a lightweight web-based query tool that supports pre-designed SQL
and SPARQL queries, addition of new queries, and visual exploration of the
provenance items by browsing the graph structure. A initial set of useful
queries enables users to browse the provenance graph and retrieve informa-
tion about clinical trial studies. Authorised users can create, execute and
12
n ≥ 0; sequential
n ≥ 0; sequential
n > 0; parallel
n ≥ 0; sequential
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Clinical
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generated
by
later generation than
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Protocol
was
generated
by later generation than
Figure 2: A TRANSFoRm provenance template taken from Query Formulation Tool,
describing creation and editing of eligibility criteria, as specified in the CRIM model
share new queries through the tool. The tool consists of two parts: Query
Collection and a Provenance Browser, as shown in Figure 4. Predefined
queries, shown in the sidebar on the left, answer specific questions from the
provenance data, with the results displayed as tabular or chart outputs. The
queries are parameterised with ontological concepts taken from the model,
thus allowing close mapping to the healthcare domain.
The provenance entities in the tabular results from the queries contain
hyperlinks that connect to the Provenance Browser tool that provides in-
teractive graphical navigation through stored provenance graphs. The user
clicks on nodes to reveal further detail about the process through ontological
annotations on each node, thereby gaining access to the wider provenance in-
formation surrounding the item of interest. The queries available range from
security-focused to ones detailing the clinical study processes. The following
are three query examples in the tool:
1. List all processes together with their authentication certificates.
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select ?p, ?said
where{
?p rdf:type opmo:Process .
?p urn:oasis:names:tc:SAML:2.0:assertion#ID ?said .
}
union
select ?p, ?said
where{
?p rdf:type opmo:Process .
?p (opmo:cause/opmo:effectInverse)* ?entity .
?entity urn:oasis:names:tc:SAML:2.0:assertion#ID ?said .
2. List all the initiating processes of all the queries that were completed
on 01/04/2012. The query uses SQL for efficiency.
SELECT OPMProcess.ProcessKey
FROM OPMProcess, OPMDependences
WHERE OPMProcess.OPMProcessEndTime BETWEEN 01/04/2012 AND 02/04/2012 AND
NOT OPMDependence.OPMDependenceEffect = OPMProcess.OPMProcessKey
3. Which databases were used to retrieve patient information of the cases
of a specific clinical trial study with artifact identified by clinicalStud-
yArtifactURI?
select ?database
where{
clinicalStudyArtifactURI rctpo:hasEligibilityCriteria ?eligCriteria .
?p rdf:type rctpo:EligibilityCriteriaQueryExecution .
?p opmo:Used ?eligCriteria .
?p1 rdf:type rctpo:EHRDBQueryExecution .
?p1 opmo:wasTriggeredBy* ?p .
?p1 opmo:Used ?database .
?database rdf:type rctpo:eHRDatabase .
}
3.2. EHR4CR (Electronic Health Records For Clinical Research)
The EHR4CR project aims to develop an integrated reusable solution
to seamlessly connect existing clinical research platforms and healthcare
networks across multiple European countries and legal frameworks. An
EHR4CR service and data integration platform will form an interoperable
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and scalable infrastructure that connects the patient data information sys-
tems in hospitals. The platform supports protocol feasibility study manage-
ment and automated queries that allow a clinical researcher to dynamically
discover eligible patients within the hospitals and recruit them for conduct-
ing clinical trials. The automated patient identification and recruitment, and
clinical trial management capacities will help to speed up the protocol feasi-
bility study and patient recruitment processes for a clinical trial and reduce
the costs. The platform will later support clinical trial execution and adverse
event reporting.
The main functionality of the EHR4CR platform is acquisition and in-
tegration of data from distributed heterogeneous healthcare information re-
sources. Queries for eligible patients are issued by clinical researchers via a
web-based workbench, the queries are distributed to endpoints (data sources
at distributed hospitals) by a query orchestrator. Each endpoint accesses
a data warehouse, which is populated with data from electronic health-
care record (EHR) systems at each hospital using an extract-transform-load
(ETL) process. The results from each endpoint are aggregated and returned
to the researcher. The platform requires many supporting services to ensure
security, translation of terminology between the different medical models used
at different sources, and a registry of endpoints, among others. Given the
distributed nature of the system and its inherent regulatory and governance
issues, replicas of each type of service are deployed in several European states.
These replicas are interconnected for enabling service integration and data
exchange with sufficient access control. This unavoidably increases the com-
plexity and difficulty for maintaining traceability and auditability of system
transactions. Performance, data quality, privacy protection and regulatory
compliance are among the major non-functional requirements.
Provenance data in EHR4CR is captured during the execution of queries,
and in the supporting data handling and access control processes. It pro-
vides reasoning information for answering questions that concerns data ac-
cess, billing, study management, and data quality issues. Motivating prove-
nance questions in EHR4CR include:
1. How did a feasibility study evolve into its current version?
2. How was a query result produced by the system?
3. How was an authorisation decision made in a system?
EHR4CR takes a model-driven data transformation approach for popu-
lating standard hospital patient data into a data warehouse to prepare infor-
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mation in a common form across hospitals, to allow queries to be expressed,
distributed and answered by the multiple sources. Records of the ETL pro-
cesses are critical for ensuring whether, and to what extent, the data can be
relied on.
The EHR4CR platform supports dynamic hospital and patient discovery
with a number of hospitals connected to the platform. Provenance graph
data is attached to each query result to explain how the result was gener-
ated. The provenance mechanism records which data sources were involved
in answering a query, and provenance information related to resource discov-
ery and binding processes to help the clinical research understand the query
results and improve the study design strategy, as it indicates what range of
sources are available or are frequently oﬄine. The provenance data can also
be used for addressing billing issues involved in the clinical trails.
Privacy protection and security compliance are addressed systematically
in the design and implementation of EHR4CR. Data access, authentication
and authorisation processes are all recorded, and it is intended that struc-
tured provenance data will replace audit logs, and allowing the interlinking of
locally generated audit trails to facilitate improved auditability for local and
cross-platform auditing. Sensitive information is not contained in the prove-
nance data returned to the researcher, but is stored locally in each subsystem
in different management realms to allow auditing and further investigation
into specific issues with finer granularity.
Finally, a clinical trial study changes over the course of time with re-
finements to eligibility criteria and repeated queries to the system. The
provenance of a study can provide a visualisable history of the study and
the reasoning behind it. This requires integrating the provenance of mul-
tiple query executions with a record of how the study itself, at the clinical
researcher’s site, has evolved over time.
As is the case in TRANSFoRm, EHR4CR records provenance according
to templates, which specify the form of provenance to be captured in an
instance-agnostic form. This enables provenance queries to be expressed, as
the structure of provenance data is known at design time. EHR4CR uses
the W3C PROV data model rather than OPM in TRANSFoRm, and does
not make use of bridging ontologies or a common information model such as
CRIM. Figure 5 shows a provenance template for documenting the execution
of a query in a component of the platform. The security-related processes
and data are indicated in grey, and form a subgraph for queries regarding
security and access control.
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In EHR4CR, provenance data is stored locally to each component in
an RDBMS. It is not stored in the form of PROV statements, but can be
exported from a component as PROV, which is used as the transport mech-
anism. In particular, a non-sensitive subset of provenance data is returned
from the hospitals used as data sources to the clinical researcher embedded
in the XML message containing the eligibility query results. This data can
then be incorporated with the researcher’s own provenance graph, regarding
the local refinement and execution of their study queries. The result is that
the researcher can query the provenance of their eligibility query results in a
local store.
We present below two brief examples of where provenance is currently
implemented and used in EHR4CR, particularly to answer question 2 above
”How was a query result produced by the system?”. These will be referred
to in the following section for illustration.
3.2.1. EHR4CR Extract-Transform-Load (ETL) use case
Each hospital EHR database is different, with a different schema, and with
different quality and types of data present, and one hospital can have multiple
EHR databases. EHR4CR requires a common data warehouse at each site, to
allow distributed querying. The overall template for recording the provenance
of these actions is shown in Figure 5. Because of the heterogeneity, in the ETL
process that transforms data from the EHR databases to the data warehouse,
different assumptions will be made at different hospitals. A key purpose of
provenance is to record the assumptions that have been made in the data
transformation. For example, to preserve confidentiality, dates of birth will
be set to the first day of the month or year to inhibit identification of the
patient. Where data is repeated across EHR databases, the one from which
a fact is drawn must be recorded. There may be several dates associated
with a specific lab test such as when the sample was taken, when it was
received by the lab and when the analysis was performed, and the warehouse
requires a single date and therefore one of these must be chosen. Observing
the provenance of an ETL process allows users to understand what data can
be relied on and to what detail.
3.2.2. EHR4CR filtering use case
There can be no assumption that the ETL process or the original data
in the EHR systems is flawless. Therefore during the determination of eli-
gible patient counts, certain clinical facts in the warehouse may have to be
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discarded because, for example, an event date was missing or a unit of mea-
surement was not in a standard representation. Thus a set of filters are used
to exclude incomplete or defective facts. A record of this filtering process
is part of the provenance returned to the clinical researcher. The discarded
facts cannot themselves be revealed to the researcher but counts of facts ac-
cepted or rejected by each filter may, so the provenance is annotated with
these counts. The counts are used by the researcher to gauge the quality
of the data and where the discard rate is very high, may explain why the
patient counts are low or zero. Thus, a provenance query on finding filter
instances which rejected 4 patients returns an RDF:
_1 rdf:type DobFilter.
_2 rdf:type Missing.
_2 IsOutcomeOf _1.
_3 rdf:type Counter.
_3 IsCounterOf _2.
_3 rdf:value 4.
The result is returned as metadata inside the protocol feasibility query
result, and then displayed in a simplified form in the user interface of the
clinical researcher.
4. Recommendations
Based on our experience in the TRANSFoRm, EHR4CR and earlier
projects, we now present a set of recommendations concerning how to model
the provenance data, and the mechanisms for its capture, storage, security,
and querying. These are described at a high level, to ensure they are re-
usable across systems yet to be designed, but with rationale provided so that
developers can understand how they should apply to their own systems.
4.1. Modelling
A key aspect of healthcare software systems is the distribution of author-
ity and control. At the time such a system is first deployed, the set of sources
and consumers of healthcare data will not be fixed, and those that are ini-
tially included will have their own local policies and practices. To be able
to answer provenance questions in such a system, all parties need to record
interoperable provenance information to a common specification. The mod-
elling allowed by that specification should also be rich enough to describe the
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processing, exchange, ownership, temporal aspects etc. of the data involved
in a computational way, else answering the questions over such large datasets
will be infeasible.
The de-facto standard for rich, interoperable provenance data is, cur-
rently, the Open Provenance Model (OPM). This has been used in a wide
range of systems and there are a number of publicly available libraries and
tools for it [42]. The forthcoming W3C PROV data model (PROV-DM) and
accompanying specifications provide the first official standard. While cur-
rently in the final stage of the standardisation process at time of writing, it
is expected to become a standard during 2013. W3C maintains a registry of
PROV implementations [43]. We note that PROV is strongly influenced by
OPM, and differs primarily in adding flexibility for describing the provenance
of mutable resources and for conveniently ascribing attribution, both aspects
relevant to healthcare data.
Both OPM and PROV contain the basic building blocks needed for provenance-
aware applications, however they should not be considered the final word on
the matter. There is frequently a need to represent structural domain infor-
mation behind provenance construction, and to include it in the provenance
traces. D-PROV, mentioned above, does that for workflow style applications,
capturing workflow graph structure, input/output data ports and other rel-
evant entities.
Recommendation 1. (Syntax) Use W3C PROV or the Open Provenance
Model for modelling provenance data recorded in an electronic healthcare sys-
tem. When choosing between the two, consider available tools and libraries
in both systems for potential reuse or adaptation.
Example: TRANSFoRm uses the RCTPO extension of OPM, containing
domain concepts and relationships.
Example: The EHR4CR ETL and filtering use cases both use an exten-
sion of PROV.
Generic provenance models, such as OPM and PROV, must be extended
with a domain- or application-specific vocabulary in order for provenance to
be informative. As with any vocabulary, usage of terminologies proprietary
to individual institutions greatly hampers interoperability. For the purposes
of informative querying, the querier must know something about the terms
used in the provenance graph.
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Recommendation 2. (Vocabulary) Institutions involved in a distributed
healthcare application should agree to a common vocabulary to use in prove-
nance constructs where possible.
Example: TRANSFoRm uses a generic interoperability data model [44]
combined with a terminology server [45] to ensure consistency across data
sources.
Example: The provenance templates used in EHR4CR filtering and ETL
processes employ a vocabulary, which is then common across the hospital
sites which locally record the provenance.
In addition to vocabularies, there is a large amount of well-standardised
information and process models to describe the domain data (e.g. EHRs,
clinical trials, drugs). Data provenance concepts associated to concepts in
standardised domain models should maintain the semantic relations between
them. Linking domain and provenance-aware models allows for a better de-
scription of procedures and dataflows, the maintenance of a bridge between
both domain and provenance data and, consequently, the possibility of per-
forming richer queries. Models should be shared with the community in order
to facilitate data interchange and the improvement of one’s own data mod-
elling process. Provenance data have to describe the state of a system in a
particular moment, and domain data evolve in time, thus provenance storage
modules have to provide a mechanism for maintaining the minimal useful in-
formation that reflects the data state, and provenance access policies have to
address the issue of restricting domain data access during query executions.
Recommendation 3. (Domain models) Link provenance models and data
with domain knowledge models and data, respectively. These may be expressed
in the form of templates, similar in form to workflows or business processes,
and should be shared with the community.
Example: TRANSFoRm RCTPO and RCTO ontologies are publicly
available and other randomized clinical trials can use them to annotate their
data, compare results and methodologies and choose the most suitable pro-
cedures accordingly.
Note that we do not prescribe particular ontologies here. There is a
wide array of sometimes overlapping biomedicine-related ontologies, and the
choice of which to use in a given application is separate from the decisions
on provenance infrastructure. Aside from ontologies of biomedical concepts,
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there will be concepts that may be captured in the provenance, whether as
typing information on the provenance graphs, or additional context infor-
mation. In some cases, these may be common across multiple distributed
biomedical applications, e.g. due to the varying quality of stored medical
data, many applications will require filtering of records before use by remote
services, and describing this in the provenance requires some vocabulary.
Defining common vocabularies for such cross-application provenance is cer-
tainly beneficial, but beyond the scope of this (or any single) paper.
When considering how to model provenance, it is natural to ask both “Are
we recording the provenance in enough detail to answer the questions that
will be asked?” and “Are we reducing performance and increasing storage
requirements by recording too much provenance data?” One observation is
that it is rare that all possible provenance questions can be known in advance:
when provenance data is present, users will realise new questions they wish
to ask. This leads to two related recommendations.
Recommendation 4. (Detail focus) Always aim to model the detail of what
happens, including each processing step and data item involved, rather than
summary information that directly answers current provenance questions.
Example: In the EHR4CR filtering use case, we do not simply record a
count of how many records have been filtered on which grounds, but express
the filtering process, with inputs and outputs to/from each filter. This allows
the filtering provenance to be interlinked with the provenance of the query
as a whole.
Instead of simply recording that “the figures produced in this feasibil-
ity study are drawn from these hospital data sources”, because this is the
primary provenance question being answered, we recommend modelling the
steps that lead from the hospital data source to the creation of the feasibility
study. Then, if later questions are asked about the influence of the infrastruc-
ture on the feasibility report contents are asked, e.g. “Were there timeouts
that meant a particular data source yielded a possibly incorrect value of zero
patients?”, then this can be answered with the given provenance information.
As there is no way to return to the past, the question could not otherwise be
answered.
While the above recommendation helps to future-proof the provenance
somewhat, it does not answer the question of the level of detail to record.
If every step of every process is recorded to the lowest level that is techni-
cally feasible, the performance and storage overhead may be unacceptable.
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We need to determine at what granularity the provenance should model pro-
cesses. One influence is that the medical domain includes many existing
semantically rich models and ontologies, and the contents of the provenance
and the granularity at which it is modelled should be dictated by these as
far as is feasible. From our experience, we suggest the following additional
guideline. For a methodological approach incorporating these two related
principles in provenance recording, see our existing work in this area [46].
Recommendation 5. (Granularity) Use the existing biomedical models and
ontologies as indicators of the level of granularity of process description that
users are likely to be interested in the future, and validate it against the
provenance questions known at design time.
Example: TRANSFoRm provenance graphs are defined in terms of tem-
plates that are designed in collaboration with the software developers who
use them to commit provenance graph fragments, and users who will need
to analyse provenance audit trails.
Example: The EHR4CR ETL provenance works at the level of a set of
clinical facts of the same type and from the same source. Thus, all diagnoses
or all results of a specific lab test will have a single provenance record if they
hailed from the same source. For a typical data warehouse, this will run into
tens or hundreds of provenance records. If the provenance were applied to
each individual fact separately, the provenance data would likely expand, by
an order of magnitude, the original data warehouse, which may already have
over 107 rows.
A danger, when considering how to model provenance, is that the per-
spective of one user group will suggest that provenance be separated into
isolated records in a way that makes it difficult to answer queries of other
groups. For example, from the perspective of a clinical researcher, it may
be natural to consider each study having its own provenance, with no or
limited connection between these provenance records. This view may be en-
couraged by the privacy and intellectual property concerns that the author
of one study should not have access to the provenance regarding another
author’s study. However, considered from a data provider’s perspective, or
that of the organisation providing the distributed infrastructure, the division
between studies is not a relevant distinction. The same data item may be
accessed within multiple studies and for the data provider’s audit purposes,
that is useful provenance knowledge. OPM and PROV allow, but do not
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require, provenance to be modelled as a single graph, in which all parts are
interconnected, because this is an accurate representation of what has oc-
curred, e.g. multiple studies can use the same data source, one study can
use multiple data sources, and they all use a common distributed infrastruc-
ture. Note that the same thing may be identified in different ways in the
provenance recorded by different organisations/actors so linkage mechanisms
should be present.
Recommendation 6. (Connectivity) Model the provenance with the expec-
tation that, if brought together, it would form a single graph describing the
full, interconnected history of the system, as opposed to being delimited into
a set of isolated records. Globally unique IDs should be used where feasible to
facilitate interlinking.
Example: In TRANSFoRm, each entity in the stored graph has a glob-
ally unique identifier, which enables connection of graphs created by different
software tools, for example Authentication Framework and Query Workbench
described above and shown as two colours in Figure 3.
Example: In EHR4CR, each query executed has a globally unique ID, as
does each hospital. Therefore, in the EHR4CR filtering use case each filtering
step in the filtering use case can be given a unique ID simply by enumerating
the steps and combining with the query ID, and each count produced by a
filter likewise.
Provenance describes not only automated processes but also human ac-
tions relevant to the data and models in the system. Human interactions
with the electronic system, and human decision-making informing those in-
teractions, are important factors in how the system operates. For example,
the approval for patient data to be used as part of a clinical study may be
affected by decisions of doctors, the patient and potentially national bodies
and others. Understanding the provenance of particular study results requires
knowing, and so having captured, the key human actions and decisions.
Recommendation 7. (Human actions) Include both salient human activi-
ties and automated processes in the model of provenance to be captured.
Example: TRANSFoRm provenance model, RCTPO is derived from
CRIM, an information model comprising human workflows as well as techni-
cal steps, and thus contains concepts modelling human decisions and actions.
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Example: In the EHR4CR platform, the selection of patients can only
be partially automated and can at best produce a shortlist that would be
narrowed down using clinical judgement. These clinical decisions will have
to be recorded (the project implementation has not reached this stage at
time of writing).
More generally, we can distinguish three key aspects that should be con-
sidered in an application’s provenance model. First, the process flow indicates
the order in which events occurred and where an action was responsible for
indirectly causing a consequence elsewhere in the system. Second, the data
flow describes where data originates and ends up, and sometimes also what
value it has. Finally, the responsibility for actions that occur should be
considered.
Recommendation 8. (Model elements) In designing the provenance model,
consider explicitly representing each element of the process flows and the data
flows, as well as the attributions of actions to users. Layering ontologies is
a useful approach that maintains logical separation between these distinct
elements.
Example: TRANSFoRm uses the RCTPO ontology to describe the pro-
cess structures and relationships between actions and users, while OPM is
employed as the basis for interactions between data and actions.
There are provenance-related mechanisms in many existing systems, in-
cluding those of the individual institutions involved in federated healthcare
systems. For example, documents will often be version controlled, audit-
ing will occur for individual databases, software will write logs to aid later
debugging, etc. Provenance aims to generalise over these different forms
of recorded history, each of which may contain relevant information for lo-
cal and remote users. The existing information could, in some cases, be
included into the provenance data through translation, e.g. relevant entries
from a database log could be parsed and translated into OPM or PROV data.
Alternatively, it could be included by reference. For example, in TRANS-
FoRm, the provenance graphs contain links to logs of where authentication
has occurred. The latter data has tighter security controls applied than the
provenance that links to it.
Recommendation 9. (Reuse of existing data) Where feasible, integrate the
data captured by existing mechanisms (version control, audit, logging, etc.)
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into the provenance record, whether by reference or translation, to provide as
rich and integrated an account as possible.
Example: TRANSFoRm provenance graphs do not store the authen-
tication information beyond the user identifier. Authentication details are
captured as a SAML [41] certificate which can be used for further audits, if
needed, outside the provenance infrastructure.
4.2. Capture
The optimal approach to capturing provenance depends on the nature of
the software system being observed. In the presence of a shared execution
middleware (e.g. workflow engine, query processor), it is convenient to em-
bed provenance support into the middleware, and let it record every action.
If such middleware does not exist, but there is a shared process model be-
tween the tools, each tool can submit template-based graph fragments to a
centralised service, that are compliant with the model definitions. Finally, in
the absence of both the shared middleware and the shared process models,
tools themselves can be left to define their own provenance traces, and trust
that there will be a consistent entity naming schema to allow for cross-tool
queries.
Even in the latter two cases, the provenance capture functionality does
not necessarily have to be created from scratch. Libraries for modelling and
serialising fragments of provenance within application code exist for both
OPM and PROV [42, 43]. Currently, Java has the widest support in terms of
libraries, but other languages, such as Python, have some implementations,
and RDF and XML are most supported for representing the provenance
data. The advantage of such libraries is that, along with the provenance
models themselves, they have a community that use them and give feedback
to improve them, which a proprietary implementation would not.
Recommendation 10. (Library reuse) If not using shared execution mid-
dleware with provenance capture support, make use of existing OPM/PROV
libraries to capture provenance data within your application code.
Example: In order to minimise the code maintenance effort, future de-
velopment of the EHR4CR and TRANSFoRm provenance infrastructures
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intend to use the PROVoKing library1, which was not available at the time
the project software was designed.
Recommendation 4 above suggested that, because not all provenance
questions are known in advance, it is preferable to record the key facts about
what has occurred, events that occur, data used, and individual’s responsi-
bility, and not just the answers to the provenance questions known at design
time. As we cannot return to the past, not documenting some event at the
time it occurs can mean that certain future provenance questions can never
be answered. This modelling decision then leads to an associated recommen-
dation regarding capture.
Recommendation 11. (Timely capture) Build the runtime provenance cap-
ture functionality into each step of the system processes, at the appropri-
ate level of granularity, using global identifiers where possible and linking to
records of preceding steps using the chosen provenance model relations.
Example: TRANSFoRm software tools write template-based provenance
graph fragments as they execute, at specified time-points.
Example: In both the EHR4CR filtering and ETL use cases, each step
of the filtering/transformation process is captured as it is executed.
With regards to performance, provenance capture (as with logging) can
have an immediate and pervasive impact on execution speed. For example,
a prior study reported an overhead of just under 10% due to provenance
capture in an application[47]. This can sometimes be mitigated by intelligent
engineering, but should not be overlooked.
Recommendation 12. (Performance testing) Test the performance over-
head of provenance capture within a small sample part of your application
to ensure it is acceptable for your application or if the technologies used and
level of detail of model need to be modified.
Example: During development, each TRANSFoRm tool performed per-
formance tests before and after introducing provenance support, and in some
cases the frequency of provenance capture was reduced so as not to adversely
affect the performance of the tool. Similarly, the usage of provenance tem-
plates facilitates profiling various stress levels on the provenance server by
simulating the load under different usage patterns and frequencies.
1https://sites.google.com/site/provokinglibrary/
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4.3. Storage
Provenance graphs are the most popular way of representing provenance
information, used in both OPM and PROV, and they can consist of thou-
sands, even millions of nodes with associated attributes. As such, they rep-
resent a special case of graph storage management allowing the use of same
basic indexing techniques, e.g. clustering and block partitioning, which is
provided by NoSQL databases such as Neo4J [48]. However, graph data
can also be stored in classical relational databases as well. The D2RQ lan-
guage [40] describes mappings between relational database schemata and
OWL/RDFS ontologies, allowing access to RDF views on a relational data.
Data partitioned in such a way can often be conveniently distributed among
several sites, which may be necessary, depending on the institution’s data
regulations. Furthermore, in such scenario, a central query resolution service
is then needed to determine if some provenance query will run across multiple
sites, and if so to resolve the node identifiers involved.
Recommendation 13. (Database structure) Consider whether provenance
storage needs to be provided in a relational database, if one is the standard
solution in the research environment, or would an RDF store or a NoSQL
graph database be an option. Privacy and data regulations will play an impor-
tant role in deciding whether and how best to distribute the data in a multiple
site scenario.
Example: TRANSFoRm data uses several ontologies and often needs to
be queried based on terms from those ontologies, so a D2RQ layer is used
over a relational database to support such queries.
Example: The EHR4CR ETL provenance data is currently stored within
a relational data warehouse since it affords querying the clinical data and
its provenance data by the same mechanism, i.e. SQL and querying is less
dependent on ontological terms.
Provenance capture is data storage of the same kind as any other data
storage in the application. For example, eligibility crtieria query results will
be received and stored at a researcher’s site, while a copy of the query will
be cached at the hospital for auditing. It makes sense, therefore to reuse
application functionality for provenance capture. In some cases, it makes
sense to store provenance data centrally, e.g. the storage and maintenance of
provenance information may be considered a matter for middleware rather
than clients. This means events can be documented remotely to where they
occur.
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Recommendation 14. (Data infrastructure) Reuse existing application in-
frastructure for provenance transmission if storing provenance centrally rather
than at each site. Messaging systems may be used to transmit data reliably
and asynchronously between application sites.
Example: TRANSFoRm provenance data is stored centrally, and trans-
mitted via the existing middleware web service infrastructure.
Example: In the EHR4CR filtering provenance use case, the provenance
captured by the hospital is encoded as RDF and is attached to the XML mes-
sage containing the query results that is returned to the clinical researcher.
No additional transmission infrastructure needed to be implemented.
Provenance data will grow over time at the rate that depends on the pat-
terns of graph segments that applications use [49]. For example, re-running
an existing ETL process would create fewer new nodes than creation of a
new clinical trial. Therefore, it is important to profile the frequency of vari-
ous provenance-generating actions. With regards to optimising storage use,
deletion policies may need to be devised to periodically remove data deemed
unnecessary for meeting regulations. To ensure that the remaining data is
still usable, it is advisable to maintain interlinked provenance graphs when
deleting data. For example, even if deleting much of the detail about how
an old EHR4CR feasibility study was executed, such as to which hospitals
the query was sent and what statistics were returned, it may be valuable to
keep the link between the query and its results in the provenance graph, as
this connection is used in historic queries, e.g. looking into rates of query
success.
Recommendation 15. (Rate of growth) Due to the typically large size of
provenance data collected over time, it is crucial to establish early on the rate
at which provenance storage requirements are expected to increase over time.
The level of detail in the model may need to be adjusted accordingly and some
deletion/archiving procedures introduced.
Example: The usage of provenance templates in TRANSFoRm enables
reliable estimates of growth based on the application usage profile, since the
size of provenance data committed in each template is known.
4.4. Security
A new set of security considerations arises for provenance data in relation
to regulating access to records of a resource, rather than the resource itself,
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e.g. whether a user is allowed to access provenance trail of a certain process,
or of a process affecting a certain data item. Even if a data item itself is
not accessible to the user, this should not necessarily restrict the user from
accessing some information about it – an auditor may not be allowed to
see a patient’s full electronic health record, but may see that the patient was
entered into a clinical trial. Therefore, the policy for access to the provenance
data items, while influenced by the access policy to subject data items, is
not necessarily identical to it.
Recommendation 16. (Permissions) When implementing provenance ac-
cess control, consider the differences in access permissions between concrete
data, and provenance records of that data.
Example: As part of its security system design, TRANSFoRm has pro-
duced an Operational Security Policy document, containing an access con-
trol model, which explicitly addresses both the various types of data and the
provenance records of those data.
Since provenance data are typically stored in relational databases or RDF
stores, one approach to access control is to leave the access control to the
storage security mechanisms. Security for database technologies has been
studied extensively in the past (see [50] for an overview) and the increasing
need for maintaining semantic resources has developed a large set of works
focused on security for RDF data [51, 52, 53].
Specific policies for provenance data can be implemented either by us-
ing either a dedicated provenance access control language [54, 55, 56], or an
existing standard such as OASIS eXtensible Access Control Markup Lan-
guage (XACML). Since XACML is not generally suitable for RDF data
[57, 54, 58, 59, 60], extensions to it are necessary [61, 60].
A key feature of a provenance access control language is a mechanism to
obfuscate the parts of the graph which the user is not allowed to view, but
which are deemed safe with the details omitted [62]. This can be done by,
for example, introducing abstract entities and processes, and by anonymising
certain nodes. Such a mechanism needs to transform the provenance graph
based on the access privileges of the user posing a query, hiding or abstract-
ing certain parts, before assembling the query response from the transformed
graph. Similarly, the ProPub system [63] computes views over provenance
graphs for the purpose of publication by satisfying a set of privacy require-
ments, specified by the user in terms of anonymising, abstracting, and hiding
certain graph segments.
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Recommendation 17. (Restrictions) When designing an access control mech-
anism for provenance data, decide whether restricted provenance information
should be completely hidden or just have details abstracted. If the latter is
the case, a mechanism is needed for answering user queries using graphs
restricted to that user’s access level.
Example: TRANSFoRm has designed a method for abstracting por-
tions of the provenance graph when answering queries so as to maximise the
amount of information required, while observing the security constraints [64].
Example: By using counts, the EHR4CR filtering provenance data pro-
vides useful information about data quality whilst not compromising the
confidentiality of patient data.
By its nature, provenance data may act as an additional layer of security
control, that is semantically enabled and thus more closely linked to the
application’s domain logic. For example, an act of extracting data from a
data source may need to have record of the authorisation made to allow
that access. However, duplication of sensitive data, such as usernames and
passwords, is rarely desirable or, indeed, feasible, and so a solution needs to
be found to link security data with provenance records.
Recommendation 18. (Sensitive data) When provenance is used to cap-
ture data about the actions of the security layers, separation of functionality
needs to be introduced to avoid inadvertently exposing sensitive data. One
way of doing so is by providing token identifiers which can then be used to
request detail from the security mechanism.
Example: In TRANSFoRm, each application can use the provenance
API to annotate the data provenance details and link them to its domain
data in an encrypted format. The access to this encrypted domain data, e.g.
user authentication details, has to be approved by the relevant module, typi-
cally the security layer or the application that has performed the provenance
capture.
4.5. Querying and visualisation
Provenance data is potentially accrued through every use of tools in a
software system, and the scale of collected data introduces a degree of com-
plexity when designing user-facing analytics. The analysis and reporting on
provenance data can be done by simply executing predefined queries based
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on some pattern and presenting them graphically, e.g. what are the proper-
ties of a query used to recruit patients for a particular clinical study, or how
was a particular process instance authenticated.
An important issue when designing the provenance data queries is to
allow for the predefined queries to evolve and be extended with new queries.
Introducing user mechanisms for adding queries to the system ensures that
new questions can be asked from the data as the understanding of the system
increases.
Recommendation 19. (Extensibility of queries) Introduce mechanisms for
dynamically adding new provenance queries to the software.
Example: TRANSFoRm provenance query tool provides several cate-
gories of parameterised queries, defined in SPARQL. These queries are ac-
cessible in an XML configuration file on the server, where a system adminis-
trator can simply add new items as needed.
Further value in querying is provided by allowing the user to examine
provenance graphs by posing open-ended queries and following the trail of the
processes and data instances to find out a greater detail of the process. This
mode of interactive, iterative querying can be supported using visualisations
based on the graphical representation of provenance data. Granularity of the
queries needs to be considered as well: a common pattern is to start with
a high-level query and then gradually narrow the query down, which should
be reflected in the query tool design. Care needs to be taken when designing
the user interface not to overwhelm the user with the scale of the conceptual
graph they are traversing.
Recommendation 20. (Interactive querying) Provenance data can be used
to answer individual queries or create tabular and graphical reports, but added
value can be obtained by exploiting the graph representation of provenance to
support open-ended, investigative querying.
Example: TRANSFoRm provides a query interface which supports a
graph view of the provenance entities in the response, allowing the user to
browse their surrounding and gain deeper understanding by directly exam-
ining the entity annotations.
If the underlying data store, relational or non-relational, has explicit sup-
port for OPM nodes and edges, it is possible to separate queries that depend
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on domain’s semantic annotations, e.g. concepts from a clinical terminology
of some hospital in EHR4CR, and those that are purely expressed in terms
of provenance concepts (all items using a certain data set). The latter can
often be optimised by breaking the abstraction and encoding them directly
in the raw query language of the database used.
Recommendation 21. (Breaking abstraction) When creating provenance
queries, whether for atomic questions, or for navigating the provenance graph
space, try to find queries that can be optimised by being directly formulated in
the underlying query language and investigate whether the performance gain
warrants this.
Example: TRANSFoRm uses D2RQ to provide a SPARQL interface
to a relational data store where the provenance data resides. While most
queries are posed in SPARQL, there are some frequent operations that are
directly implemented as SQL for efficiency purposes. Typical example are
the TRANSFoRm live activity reporting portal components which may be
in constant use by multiple users.
Example: In the EHR4CR ETL case, the provenance is abstracted and
kept in the data warehouse’s SQL database. Instead of putting the prove-
nance graph itself in the database, there is a well-defined mapping from the
columns in the database to a provenance graph (following a template).
5. Conclusions
The software landscape in biomedical research is vast and disconnected,
encompassing electronic health record systems, genetic data repositories,
clinical trial systems, and diagnostic support systems, among others. Re-
search tasks are executed by numerous actors, including researchers and
clinical staff, from multiple organisations and with different data governance
restrictions. In order to ensure that the research results are auditable, veri-
fiable, and reproducible, the provenance of both data and processes involved
needs to be captured in a consistent, interoperable, confidentiality-preserving
manner across all software tools used in the research task.
While progress has been made in developing standardised, extensible, flex-
ible provenance models suited to represent this provenance data, this alone
does not mean that the way to model, capture, securely store and query
provenance in a given application is a trivial problem. In addition, there
32
are multiple levels of modelling involved, starting from low-level provenance
specific constructs, to higher level ones that correspond to domain and appli-
cation concepts that are often taken from existing models. Developers need
not only to know which technologies to use, but what principles to follow in
their designs.
In this paper, we have laid out a set of recommendations for implementing
provenance through analysing our experience in developing two large-scale
biomedical research systems. These are not meant to be definite and im-
mutable, but rather a starting point for researchers that will eventually be
enriched and improved by contributions of others. Ultimately, as the prove-
nance technology matures, this work will give rise to more formal software
engineering techniques that will facilitate provenance implementation across
a broad range of software tools in biomedical domain and beyond.
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Figure 4: TRANSFoRm query tool showing the graph area surrounding a selected item -
StudyProtocolDefinitionProcess. The menu bar on the left contains configured queries.
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prov:used
prov:used
prov:wasAttributedTo
ehr4cr:
authorisationDecision
ehr4cr:
generateAuditTrail
ehr4cr:
auditTrail
prov:wasGeneratedBy
prov:hadMember
ehr4cr:
processQueryRequest
ehr4cr:
invokeDownStream
Service
ehr4cr:
downStreamQuery
Request
ehr4cr:
queryResult
ehr4cr:
LocalAccessControlPolicy
prov:wasGeneratedBy
prov:used
ehr4cr:
ServiceResponse
ehr4cr:
QueryRequestQueue
ehr4cr:
QueryResultQueue
ehr4cr:
saveQueryResult
ehr4cr:
SaveQueryRequest
ehr4cr:
discoverResources
ehr4cr:
ResourceURIs
ehr4cr:
responseToRequester
ehr4cr:
processQueryResults
ehr4cr:
autenticationResult
ehr4cr:
invokeSecurityService
prov:used
prov:wasInformedBy
prov:wasGeneratedBy
prov:used
prov:used
prov:wasGeneratedBy
prov:hadMember
prov:used
prov:wasInformedBy
prov:wasGeneratedBy
prov:used
prov:used
prov:wasGeneratedBy
prov:used
prov:used
prov:used
prov:wasGeneratedBy
prov:used
ehr4cr:
processQueryRequest
prov:used
prov:used
prov:wasGeneratedBy
prov:used
Figure 5: A provenance recording template for integrated auditing
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1. Syntax
Use W3C PROV or the Open Provenance Model for modelling provenance
data recorded in an electronic healthcare system. When choosing between
the two, consider available tools and libraries in both systems for potential
reuse or adaptation.
2. Vocabulary
Institutions involved in a distributed healthcare application should agree to
a common vocabulary for describing provenance entities where possible.
3. Domain models
Link provenance models and data with domain knowledge models and data,
respectively. These may be expressed in the form of templates, similar in form
to workflows or business processes, and should be shared with the community.
4. Detail focus
Always aim to model the detail of what happens, including each processing
step and data item involved, rather than summary information that directly
answers current provenance questions.
5. Granularity
Use the existing biomedical models and ontologies as indicators of the level
of granularity of process description that users are likely to be interested in
the future, and validate it against the provenance questions known at design
time.
6. Connectivity
Model the provenance with the expectation that, if brought together, it would
form a single graph describing the full, interconnected history of the system,
as opposed to being delimited into a set of isolated records. Globally unique
IDs should be used where feasible to facilitate interlinking.
7. Human actions
Include both salient human activities and automated processes in the model
of provenance to be captured.
8. Model elements
In designing the provenance model, consider explicitly representing each el-
ement of the process flows and the data flows, as well as the attributions of
actions to users.
Table 1: Overview of recommendations (1)
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9. Reuse of existing data
Where feasible, integrate the data captured by existing mechanisms (version
control, audit, logging, etc.) into the provenance record, whether by reference
or translation, to provide as rich and integrated an account as possible.
10. Library reuse
If not using shared execution middleware with provenance capture support,
make use of existing OPM/PROV libraries to capture provenance data within
your application code.
11. Timely capture
Build the runtime provenance capture functionality into each step of the sys-
tem processes, at the appropriate level of granularity, using global identifiers
where possible and linking to records of preceding steps using the chosen
provenance model relations.
12. Performance testing
Test the performance overhead of provenance capture within a small sample
part of your application to ensure it is acceptable for your application or if
the technologies used and level of detail of model need to be modified.
13. Database structure
Consider whether provenance storage needs to be provided in a relational
database, if one is the standard solution in the research environment, or
would an RDF store or a NoSQL graph database be an option. Privacy and
data regulations will play an important role in deciding whether and how
best to distribute the data in a multiple site scenario.
14. Data infrastructure
Reuse existing application infrastructure for provenance transmission if stor-
ing provenance centrally rather than at each site. Messaging systems may be
used to transmit data reliably and asynchronously between application sites.
15. Rate of growth
Due to the typically large size of provenance data collected over time, it is
crucial to establish early on the rate at which provenance storage require-
ments are expected to increase over time. The level of detail in the model
may need to be adjusted accordingly and some deletion/archiving procedures
introduced.
16. Permissions
When implementing provenance access control, consider the differences in
access permissions between concrete data, and provenance records of that
data.
Table 2: Overview of recommendations (2)
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17. Restrictions
When designing an access control mechanism for provenance data, decide
whether restricted provenance information should be completely hidden or
just have details abstracted. If the latter is the case, a mechanism is needed
for answering user queries using graphs restricted to that user’s access level.
18. Sensitive data
When provenance is used to capture data about the actions of the security
layers, separation of functionality needs to be introduced to avoid inadver-
tently exposing sensitive data. One way of doing so is by providing token
identifiers which can then be used to request detail from the security mech-
anism.
19. Extensible queries
Introduce mechanisms for dynamically adding new provenance queries to the
software.
20. Interactive querying
Provenance data can be used to answer individual queries or create tabu-
lar and graphical reports, but added value can be obtained by exploiting
the graph representation of provenance to support open-ended, investigative
querying.
21. Breaking abstraction
When creating provenance queries, whether for atomic questions, or for nav-
igating the provenance graph space, try to find queries that can be optimised
by being directly formulated in the underlying query language and investigate
whether the performance gain warrants this.
Table 3: Overview of recommendations (3)
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